
Bristol-Myers Squibb Company BMY
$ 62.54
0.27%
Annual report 2025
added 02-11-2026
Bristol-Myers Squibb Company Cost of Revenue 2011-2026 | BMY
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.9 B | 14 B | 10.7 B | 10.1 B | 9.94 B | 11.8 B | 8.08 B | 6.47 B | 6.01 B | 4.97 B | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14 B | 4.97 B | 9.6 B |
Quarterly Cost of Revenue Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.37 B | 3.03 B | 2.96 B | 3.27 B | 2.93 B | 2.51 B | 2.88 B | 2.57 B | - | 2.35 B | 2.72 B | 2.47 B | - | 2.29 B | 2.45 B | 2.84 B | - | 2.5 B | 2.7 B | 3.66 B | - | 1.79 B | 1.97 B | 1.82 B | - | 1.65 B | 1.62 B | 1.58 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.66 B | 1.58 B | 2.52 B |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
32.2 M | - | 2.43 % | $ 254 M | ||
|
Alector
ALEC
|
51.8 M | $ 2.11 | -13.17 % | $ 217 M | ||
|
I-Mab
IMAB
|
27.2 M | - | - | $ 866 M | ||
|
Axsome Therapeutics
AXSM
|
47.5 M | $ 164.13 | 0.15 % | $ 8.17 B | ||
|
AgeX Therapeutics
AGE
|
40 K | - | -10.17 % | $ 12.2 K | ||
|
Aytu BioScience
AYTU
|
20.6 M | $ 2.49 | -3.11 % | $ 15.6 M | ||
|
Midatech Pharma plc
MTP
|
926 K | - | -18.52 % | $ 27.3 M | ||
|
BridgeBio Pharma
BBIO
|
21 M | $ 64.24 | -3.37 % | $ 12.3 B | ||
|
BioCardia
BCDA
|
4 K | $ 1.37 | 6.2 % | $ 29 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
12.3 M | $ 8.61 | -1.66 % | $ 1.78 B | ||
|
Acorda Therapeutics
ACOR
|
15.3 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
76 K | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
100 K | - | - | $ 86.2 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
91.7 M | $ 11.47 | -0.43 % | $ 742 M | ||
|
AIkido Pharma
AIKI
|
9 K | - | 1.93 % | $ 17.4 M | ||
|
Biogen
BIIB
|
2.4 B | $ 187.68 | -2.16 % | $ 27.5 B | ||
|
BioVie
BIVI
|
312 K | $ 1.38 | -0.01 % | $ 2.04 M | ||
|
Albireo Pharma
ALBO
|
1.36 M | - | -0.23 % | $ 916 M | ||
|
BioMarin Pharmaceutical
BMRN
|
717 M | $ 60.68 | -1.7 % | $ 11.6 B | ||
|
BioNTech SE
BNTX
|
2.91 B | $ 109.85 | -0.34 % | $ 27.2 B | ||
|
Aeterna Zentaris
AEZS
|
90 K | - | 5.93 % | $ 314 M | ||
|
Ampio Pharmaceuticals
AMPE
|
369 K | - | -11.43 % | $ 502 K | ||
|
BioXcel Therapeutics
BTAI
|
2.14 M | $ 1.63 | -2.69 % | $ 4.13 M |